Literature DB >> 19854524

Justification for inter-fraction correction of catheter movement in fractionated high dose-rate brachytherapy treatment of prostate cancer.

Tania Simnor1, Sonia Li, Gerry Lowe, Peter Ostler, Linda Bryant, Caroline Chapman, Dave Inchley, Peter J Hoskin.   

Abstract

BACKGROUND AND
PURPOSE: Fractionated high dose-rate (HDR) brachytherapy in the treatment of prostate cancer relies on reproducible catheter positions for each fraction to ensure adequate tumour coverage while minimising dose to normal tissues. Peri-prostatic oedema may cause caudal displacement of the catheters relative to the prostate gland between fractions. This can be corrected for by changing source dwell positions or by physical re-advancement of catheters before treatment.
MATERIALS AND METHODS: Data for 20 consecutive monotherapy patients receiving three HDR fractions of 10.5 Gy per fraction over 2 days were analysed retrospectively. Pre-treatment CT scans were used to assess the effect of catheter movement between fractions on implant quality, with and without movement correction. Implant quality was evaluated using dosimetric parameters.
RESULTS: Compared to the first fraction (f1) the mean inter-fraction caudal movement relative to the prostate base was 7.9 mm (f2) (range 0-21 mm) and 3.9 mm (f3) (range 0-25.5 mm). PTV D90% was reduced without movement correction by a mean of 27.8% (f2) and 32.3% (f3), compared with 5.3% and 5.1%, respectively, with catheter movement correction. Dose to 2 cc of the rectum increased by a mean of 0.69 (f2) and 0.76 Gy (f3) compared with an increase of 0.03 and 0.04 Gy, respectively, with correction. The urethra V12 also increased by a mean of 0.36 (f2) and 0.39 Gy (f3) compared with 0.06 and 0.16 Gy, respectively, with correction.
CONCLUSIONS: Inter-fraction correction for catheter movement using pre-treatment imaging is critical to maintain the quality of an implant. Without movement correction there is significant risk of tumour under-dosage and normal tissue over-dosage. The findings of this study justify additional imaging between fractions in order to carry out correction.

Entities:  

Mesh:

Year:  2009        PMID: 19854524     DOI: 10.1016/j.radonc.2009.09.015

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  17 in total

1.  Improved electromagnetic tracking for catheter path reconstruction with application in high-dose-rate brachytherapy.

Authors:  Elodie Lugez; Hossein Sadjadi; Chandra P Joshi; Selim G Akl; Gabor Fichtinger
Journal:  Int J Comput Assist Radiol Surg       Date:  2017-02-18       Impact factor: 2.924

Review 2.  Magnetic resonance image guided brachytherapy.

Authors:  Kari Tanderup; Akila N Viswanathan; Christian Kirisits; Steven J Frank
Journal:  Semin Radiat Oncol       Date:  2014-07       Impact factor: 5.934

3.  High-dose-rate interstitial brachytherapy for gynecologic malignancies--dosimetric changes during treatment period.

Authors:  Tsuyoshi Onoe; Takayuki Nose; Hideomi Yamashita; Minoru Yoshioka; Takashi Toshiyasu; Takuyo Kozuka; Masahiko Oguchi; Keiichi Nakagawa
Journal:  J Radiat Res       Date:  2013-01-07       Impact factor: 2.724

4.  In vivo assessment of catheter positioning accuracy and prolonged irradiation time on liver tolerance dose after single-fraction 192Ir high-dose-rate brachytherapy.

Authors:  Lutz Lüdemann; Christian Wybranski; Max Seidensticker; Konrad Mohnike; Siegfried Kropf; Peter Wust; Jens Ricke
Journal:  Radiat Oncol       Date:  2011-09-05       Impact factor: 3.481

Review 5.  Review of advanced catheter technologies in radiation oncology brachytherapy procedures.

Authors:  Jun Zhou; Leonid Zamdborg; Evelyn Sebastian
Journal:  Cancer Manag Res       Date:  2015-07-16       Impact factor: 3.989

Review 6.  The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer.

Authors:  Yasuo Yoshioka; Ken Yoshida; Hideya Yamazaki; Norio Nonomura; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2013-03-29       Impact factor: 2.724

7.  Day to day treatment variations of accelerated partial breast brachytherapy using a multi-lumen balloon.

Authors:  Hsiang-Chi Kuo; Keyur J Mehta; Linda Hong; Ravindra Yaparpalvi; Leslie L Montgomery; William Bodner; Wolfgang A Tomé; Shalom Kalnicki
Journal:  J Contemp Brachytherapy       Date:  2014-04-03

8.  Effect of using different U/S probe Standoff materials in image geometry for interventional procedures: the example of prostate.

Authors:  Stefanos Diamantopoulos; Natasa Milickovic; Saeed Butt; Zaira Katsilieri; Vasiliki Kefala; Pawel Zogal; George Sakas; Dimos Baltas
Journal:  J Contemp Brachytherapy       Date:  2011-12-30

9.  Prostate cancer boost using high-dose-rate brachytherapy: early toxicity analysis of 3 different fractionation schemes.

Authors:  Hussam Hijazi; Daniel Chevallier; Jocelyn Gal; Marie-Eve Chand; Mathieu Gautier; Jean-Michel Hannoun-Levi
Journal:  J Contemp Brachytherapy       Date:  2013-10-31

Review 10.  Review of clinical brachytherapy uncertainties: analysis guidelines of GEC-ESTRO and the AAPM.

Authors:  Christian Kirisits; Mark J Rivard; Dimos Baltas; Facundo Ballester; Marisol De Brabandere; Rob van der Laarse; Yury Niatsetski; Panagiotis Papagiannis; Taran Paulsen Hellebust; Jose Perez-Calatayud; Kari Tanderup; Jack L M Venselaar; Frank-André Siebert
Journal:  Radiother Oncol       Date:  2013-11-30       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.